Gastrointestinal Tumors Clinical Trial
Official title:
The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study
Malnutrition occurs in up to 50% of patients requiring elective surgery for neoplastic
diseases. It exerts a detrimental influence on outcome of surgery, because it can suppress
immune function, exaggerate stress response and cause organ system dysfunction. Increased
susceptibility to infection, protracted wound healing, impaired blood clotting and vessel
wall fragility have been shown to be the leading causes of postoperative morbidity and
mortality in malnourished patients undergoing major surgical resections.
This trial is designed as a prospective randomized, double-blinded, placebo-controlled pilot
study in a academic single center in Switzerland. A total of 50 malnourished patients with
gastro-intestinal tumors will receive orally glutamine or placebo-treatment during a period
of 5 days prior to surgery. The investigators hypothesize that oral Glutamine administration
is feasible, well tolerated, will decrease postoperative morbidity, will suppress
postoperative cell damage and inflammatory response, and will improve the perioperative
immunocompetence of the patients.
Background
Malnutrition occurs in up to 50% of patients requiring elective surgery for neoplastic
diseases. It exerts a detrimental influence on outcome of surgery, because it can suppress
immune function, exaggerate stress response and cause organ system dysfunction. Increased
susceptibility to infection, protracted wound healing, impaired blood clotting and vessel
wall fragility have been shown to be the leading causes of postoperative morbidity and
mortality in malnourished patients undergoing major surgical resections.
Immuno- or pharmaconutrition, defined as enteral or parenteral nutritional therapy based on a
variety of products, such as omega-3-fatty acids, glutamine, arginine, sulfur-containing
amino acids, nucleotides and anti-oxidants, is thought to have beneficial effects on
postoperative recovery in a wide variety of surgical patients. Studies have shown its
clinical effectiveness in terms of reduced postoperative complications, shortening the
hospital stay and reduced hospitalization costs. Torosian et al. showed that severely
malnourished patients benefit from preoperative nutrition, which reduce postoperative
complications by 20%.
Although there is clinical evidence for the administration of immunonutrition to patients in
the perioperative period, our understanding of the optimal type and time of immunonutrition,
the characteristics of patients that benefit most, as well as the immunological mechanisms
responsible for its beneficial effect is limited.
Objective
To assess in malnourished cancer patients the effect of 30g oral glutamine/day (3 sachets
KABI® glutamine, Fresenius Kabi/day) for a preoperative course of 5 days on:
1. Postoperative morbidity (surgical site infections, pneumonia, sepsis, incidence of wound
and fascial dehiscence, incisional hernia, anastomotic break down)
2. Nutritional status of the patients
3. Postoperative cell damage and inflammatory response
4. Perioperative immunocompetence
Methods
Seven days before surgery, the patients will receive a tetanus booster shot and will be
randomly enrolled in either the 'glutamine group' or into the 'placebo group'. The patients
as well as the responsible surgeons will be blinded.
- Patients in the 'glutamine group' will receive 30g oral glutamine / day for 5 days
before surgery.
- Patients in the 'control group' will receive 30g oral maltodextrin / day for 5 days
before surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05922358 -
Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT06152757 -
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
|
Early Phase 1 | |
Terminated |
NCT04171141 -
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03833700 -
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
|
Phase 1 | |
Recruiting |
NCT06085365 -
Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors
|
Phase 3 | |
Completed |
NCT01640665 -
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
|
Phase 1 | |
Recruiting |
NCT04629326 -
PD-L1 Targeting Molecular Imaging of Solid Tumors
|
N/A | |
Recruiting |
NCT05981235 -
Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
|
Phase 1 | |
Recruiting |
NCT05262335 -
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
|
Phase 2 | |
Terminated |
NCT01648465 -
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06263205 -
Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques
|
N/A |